Steve Bryson, PhD, science writer —

At the onset of atypical hemolytic uremic syndrome (aHUS) among children in India, high levels of antibodies against a complement protein called factor B were tied to disease severity, a new study by researchers in New Delhi revealed. Importantly, all pediatric patients with genetic mutations associated with aHUS did…

A COVID-19 vaccine may have triggered the development of two autoimmune diseases, atypical hemolytic uremic syndrome (aHUS) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), which are associated with damage to small blood vessels and the kidneys, in a 67-year-old man three weeks after vaccination, according to a case…

Genetic screening of a large group of people suspected of having atypical hemolytic uremic syndrome (aHUS) detected very few gene variants likely to be associated with the condition, a study reported. Despite signs of aHUS, around two-thirds of those tested had no evidence of any known disease-causing variants. These…

Areas of brain damage caused by a lack of blood supply were found in a patient with atypical hemolytic uremic syndrome (aHUS), a case study reports. Treatment with Soliris (eculizumab) ultimately resolved the patient’s neurological symptoms. According to the authors, the case shows this type of brain damage…

Treatment with the drug Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) initially failed to ease the symptoms of a middle-age woman with AHUS and multiorgan involvement, a case study reported. Higher Soliris doses eventually eased disease symptoms in all organs except the kidneys, which had to be replaced…

Preventive treatment with Soliris (eculizumab) before surgery dramatically improved kidney transplant outcomes in people with atypical hemolytic uremic syndrome (aHUS), according to a recent study. One year after the surgeries, 97% of transplanted kidneys still functioned in Soliris-treated patients. In those who did not receive preventive treatment, that…

NovelMed has been cleared to begin patient testing of NM8074, an investigational antibody-based therapy for atypical hemolytic uremic syndrome (aHUS) that is not expected to carry a risk of treatment-related infections. The therapy candidate is designed to block the complement cascade — a part of the immune system…

Using Soliris (eculizumab) in combination with the blood cancer treatment obinutuzumab successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) after kidney transplant in a 45-year-old woman, a case study reported for the first time. The woman lost kidney function due to a rare occurrence of aHUS…

Proteins called factor Ba and sC5b-9 measured in the blood and urine of people with atypical hemolytic uremic syndrome (aHUS) showed they are clinically useful to mark features of the condition, a study showed. Thrombomodulin, a marker of blood vessel damage, and the inflammatory indicator sTNF-RI, combined with factor…

Soliris (eculizumab) safely and effectively treated chronic kidney disease in children with atypical hemolytic uremic syndrome (aHUS), a review study confirmed. Researchers suggested that more research is necessary, however, to establish its effectiveness, safety, and time of discontinuation in the long term. The review study, “The treatment…